iOrganBio, an innovator in intelligent cell manufacturing, today announced the appointment of Lee L. Rubin, Ph.D., to its Scientific Advisory Board. Dr. Rubin is a leading authority in stem cell biology, regenerative medicine, and translational neuroscience, whose research has advanced the understanding of neurodegenerative diseases and contributed to the development of multiple therapeutic candidates.
Dr. Rubin serves as Co-Director and Principal Faculty of the Harvard Stem Cell Institute and Professor in Harvard's Department of Stem Cell and Regenerative Biology. His pioneering work spans blood-brain barrier biology, neural stem cell differentiation, disease modeling using patient-derived induced pluripotent stem cells, and the discovery of therapeutic candidates for disorders including Parkinson's disease, amyotrophic lateral sclerosis (ALS), and spinal muscular atrophy (SMA). His appointment signals iOrganBio's strategic expansion into neurological applications of its platform.
iOrganBio's CellForge platform combines AI prediction, biological sensing, and automated 3D incubation to engineer human cells and organoids with greater precision and consistency. This enables scalable production for disease modeling, drug discovery, and cell therapy development. The platform's core is the functional human CellAtlas, a comprehensive reference built from single-cell and multi-omics data that provides digital blueprints for each cell type. This closed-loop process delivers accuracy, efficiency, and quality needed to accelerate research.
“We are thrilled to welcome Lee to our Scientific Advisory Board,” said iOrganBio CEO in the announcement. “His deep expertise in stem cell biology and neurodegenerative disease will be invaluable as we expand our platform into neurological applications and work to bring more predictive human models to drug discovery.”
The addition of Dr. Rubin comes as iOrganBio focuses on FDA-aligned New Approach Methodologies (NAMs) that aim to reduce reliance on animal testing. By combining AI-driven manufacturing with expert guidance, the company hopes to accelerate the development of therapies for complex neurological conditions. For more information about iOrganBio and its CellForge platform, visit iOrgan.Bio.
